Navigation Links
Arteriocyte Named Top Biotech Start Up Venture by the Ohio Venture Association for 2010
Date:6/28/2010

CLEVELAND, June 28 /PRNewswire/ -- Arteriocyte, Inc., was honored Friday by the Ohio Venture Association as a Venture of Year Award Finalist. Founded in 2004 to develop proprietary stem cell and tissue engineering based therapies, Arteriocyte focuses on developing commercially available stem cell based therapies using multiple sources of adult derived stem cells (marrow, peripheral cord blood, and cartilage) for delivery to injured tissues in order to speed repair and improve function. In six short years, the company has grown from one employee to more than 67 employees located throughout the world and has rapidly transitioned from a basic research project into a fully integrated R&D and commercial product company with revenue growth of 45% in 2009, producing and distributing a broad portfolio of research based stem cell culturing systems and FDA approved point-of-care medical devices designed to improve surgical outcomes.

(Logo:  http://photos.prnewswire.com/prnh/20100624/ALOGO )

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100624/ALOGO )

Already in 2010, Arteriocyte has been awarded more than $8 Million in competitive grants and federal research contracts to fuel clinical implementation and further commercialization of its unique technologies. The company has capitalized on its top-ranked 2009 Ohio Third Frontier Research Commercialization Program award to initiate four separate clinical trials to evaluate rapid, bedside stem cell therapies in cardiovascular disease, peripheral vascular disease, and prevention of surgical site infection. Additionally, this year the company will begin clinical evaluation of its Magellan Platelet separation technology for Amputation Prevention in the setting of Compartment Syndrome, the first of three clinical research programs funded by the Department of Defense in partnership with the Army Institute of Surgical Research that focus on developing cellular therapies for Battlefield Wounded Soldiers. Arteriocyte has also completed  the transfer of its proprietary NANEX™ stem cell expansion technology (licensed from Johns Hopkins University) and begun production at its Cleveland facility.

"We're pleased to be recognized by our peers in the start-up and venture community," said Arteriocyte CEO Don Brown. "But really, the recognition should go to the State of Ohio for creating an environment that fosters rapid biotech businesses growth. Ohio has helped our company benefit from a rich hiring pool of incredibly talented people, yielded multiple collaborative university research partnerships, and fueled our growth with one of the most business friendly state investment programs anywhere: Ohio's Third Frontier Program."

The Ohio Venture Association is a Northeast Ohio based organization that provides a forum to bring together entrepreneurs, new business ventures and venture capital. Other honorees for 2010 include PartSource and Findaway World.

About Arteriocyte

Arteriocyte, a clinical stage Biotechnology Company with facilities in Maryland, Massachusetts, Ohio, Texas and Utah, develops proprietary stem cell therapies for human clinical applications. In 2007, Arteriocyte partnered with DW Healthcare Partners (a leading healthcare private equity partnership) to acquire the Magellan autologous platelet separation device technology from Medtronic. Today Arteriocyte's Medical Systems unit distributes the Magellan system worldwide.


'/>"/>
SOURCE Arteriocyte, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. DuPont Named to Biofuels Digest 2010 “Transformative Technologies 303
2. Sandia researchers Phillips, Moody named MRS Fellows
3. ChemoCentryx President and CEO, Thomas J. Schall, Ph.D., Named Ernst & Young Entrepreneur Of The Year 2010 Award Finalist in Northern California
4. Profil Institutes Dr. Marcus Hompesch Named Finalist in Ernst & Young Entrepreneur Of The Year(R) 2010 Award for Second Year in a Row
5. Frommer Lawrence & Haugs Thomas J. Kowalski Named to the International Whos Who of Patent Attorneys
6. Best of Show Award Winners Named at Bio-IT World Conference & Expo
7. Frchet Named Vice President for Research at Kaust
8. US Oncology Named to FORTUNE Magazines Worlds Most Admired Companies List for Fifth Time
9. Medtronic Named Among Worlds Most Innovative Companies by MIT Technology Review
10. Fate Therapeutics Named One of the 50 Most Innovative Companies in the World by MITs Technology Review
11. Riemer Named President of Medical Device Manufacturer MRPC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... LOUISVILLE, Ky. , Jan. 16, 2017  Eurofins ... service, which will allow more customers to receive their ... price premium or compromise in quality found with other ... the United States at no additional ... variety of routine genetic studies, including DNA sequencing, genotyping, ...
(Date:1/13/2017)... ... 13, 2017 , ... Two Kalamazoo entrepreneurs have launched AgTonik ... that farms, greenhouses and hydroponics operations use to increase yields and promote plant ... segments of customers using this high grade fulvic acid extracted from a mineral ...
(Date:1/12/2017)... Ca (PRWEB) , ... January ... ... low-cost, disposable devices with short response times capable of performing routine electrochemical ... fields, disposable screen-printed electrodes provide fast, sensitive detection and quantification of various ...
(Date:1/12/2017)... January 12, 2017 A new report published by Allied Market ... Global Opportunity Analysis and Industry Forecast, 2014-2022," projects that the global in vitro toxicity ... at a CAGR of 15.07% during the forecast period. ... ... ...
Breaking Biology Technology:
(Date:1/4/2017)... Jan. 4, 2017  CES 2017 – Valencell ... technology, today announced the launch of two new ... the highly-accurate biometric sensor modules that incorporate the ... experience and expertise. The two new designs include ... for hearables, and Benchmark BW2.0, a 2-LED version ...
(Date:12/22/2016)... -- SuperCom (NASDAQ:   SPCB ... Public Safety, HealthCare, and Finance sectors announced today that Leaders in ... implement and deploy a community-based supportive services program to reduce recidivism ... further expanding its presence in the state. ... This new program, which is expected to ...
(Date:12/19/2016)... España y TORONTO , 19 de diciembre de ... Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo ... varios tipos de tumor en 2017, con múltiples sitios previstos a ... ... con objetivo en el factor inhibidor de leucemia (LIF), una citoquina ...
Breaking Biology News(10 mins):